Comparative genomic hybridization (CGH): ten years of substantial progress in human solid tumor molecular cytogenetics.
Data from ten years of research using comparative genomic hybridization (CGH) for the detection of chromosomal alterations in human solid tumors are concisely reviewed. By use of a basic methodology with some variations more or less specific patterns of genomic imbalances were found in a large number of tumors of various entities. Specific gains and losses of genomic material have not only opened the way to the detection of a series of cancer-related genes but also to clinical implications. Not only several areas of basic oncogenetic research, but also differential diagnosis, prognosis of disease progression, and therapeutic decisions have profited by CGH.
Gebhart
E
E
Institute of Human Genetics, University of Erlangen-Nürnberg, Erlangen, Germany. egebhart@humgenet.uni-erlangen.de
D022981:Allelic Imbalance; D000782:Aneuploidy; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics* / Q000648:ultrastructure; D004273:DNA, Neoplasm / Q000235:genetics*; D018450:Disease Progression; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence / Q000639:trends; D008297:Male; D016296:Mutagenesis; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology; D009693:Nucleic Acid Hybridization
D004273:DNA, Neoplasm